Glycemic Normalization Immediately Following Vertical Sleeve Gastrectomy in Adolescents With Type 2 Diabetes From the ST2OMP Study Authors: Natalie Segev, Kristen J. Nadeau, Megan Kelsey, Lisa R. Schaaf, Amy Baumgartner, Allen Riegler, Kelly Wiitala, Todd M. Jenkins, Stavra A. Xanthakos, Michael A. Helmrath, Thomas H. Inge, Amy Sanghavi Shah Published: 2026 ABSTRACT ABSTRACTAimYouth‐onset type 2 diabetes and obesity are rising public health burdens. While newer type 2 diabetes medications lower HbA1c, their impact on paediatric weight loss is inconsistent. In contrast, bariatric surgery improves glycemia and weight in youth and adults, though glycemia post‐vertical sleeve gastrectomy (VSG), now the predominant bariatric surgery in youth, remains unstudied in youth‐onset type 2 diabetes. We aimed to assess immediate post‐VSG glycemic patterns using continuous glucose monitoring (CGM) in adolescents with type 2 diabetes.Materials and MethodsIn the Surgical or Medical Treatment for Paediatric Type 2 Diabetes (ST2OMP) study, 73 adolescents with type 2 diabetes underwent 14 days of CGM monitoring: 33 participants beginning in the 1–2 days post‐VSG (mean age 17.6 years, 67% female, HbA1c 7.2%, BMI 50.0 kg/m2) and 40 participants receiving advanced medical therapy (AMT) (mean age 16.9 years, 53% female, HbA1c 7.8%, BMI 42.2 kg/m2). CGM analyses included glucose management indicator (GMI), time in range, coefficient of variability, standard deviation, mean amplitude glycemic excursion, percent > 140, 180, and 200, percent < 70 and 60 mg/dL, 7 a.m., and midnight‐6 a.m.ResultsMean glucose was 84.3 ± 23.4 in the post‐VSG group versus 149.8 ± 78.8 mg/dL in the AMT group (p < 0.001). Mean CGM GMI was normal (5.3%, 34 mmol/mol) post‐VSG versus in the diabetes range (6.9%, 52 nmol/mol) with AMT (p < 0.001). VSG participants spent more time < 70 mg/dL, 55 mg/dL, and 45 mg/dL (all p < 0.01). After BMI adjustment, preoperative HbA1c predicted postoperative glucose metrics.ConclusionAdolescents with type 2 diabetes experience early glycemic normalization post‐VSG, even before major weight loss. Introduction Youth‐onset type 2 diabetes has a more aggressive course than when diagnosed in adulthood [1, 2]. Although some newer pharmacotherapies once limited to adults are now approved for paediatrics, studies show less consistent impact on weight in youth, high cost, no durability of effect once medications are stopped, and unknown long‐term safety profile, leaving paediatric obesity a significant public health concern [3, 4]. Effective treatments addressing both obesity and type 2 diabetes are needed. Recent guidelines highlight metabolic bariatric surgery (MBS) as a long‐term intervention, achieving substantial weight loss and diabetes remission in adolescents and adults up to 10 years post‐surgery [5, 6, 7, 8, 9, 10, 11, 12]. In adults, glycemic normalization often precedes significant weight loss, suggesting additional mechanisms beyond weight reduction [13]. The Surgical or Medical Treatment for Paediatric Type 2 Diabetes (ST2OMP) study (NCT04128995) compares outcomes, including glycemia, between advanced medical therapy (AMT) and vertical sleeve gastrectomy (VSG) [14]. In ST2OMP, continuous glucose monitoring (CGM) assessed glycemic patterns and variability in two cohorts of adolescents with obesity and type 2 diabetes, one group immediately following VSG before significant weight loss and one group continuing on AMT. Understanding these glycemic patterns is critical to uncovering early metabolic effects of VSG, now the predominant form of MBS in adolescents. We hypothesized VSG would yield rapid glycemic improvement, reduced variability, and increased time in range when compared to a medically treated AMT control group. Materials and Methods ST2OMP recruited adolescents aged 13–19 years with type 2 diabetes and obesity (BMI > 35 kg/m2 or > 120% of the 95th percentile) from two quaternary care children's hospitals, Cincinnati Children's Hospital and Children's Hospital Colorado, into an open‐label clinical trial. As part of standardized routine clinical care at both sites, adolescents meeting guideline‐based eligibility criteria for metabolic and bariatric surgery were counselled regarding both medical and surgical treatment options, and treatment selection was determined by participant/family preference in conjunction with their clinical care team independent of the trial. Study design details were previously published [14]. Prior to the 6‐month run‐in period, participants in both groups were managed medically by their diabetes providers using antidiabetic pharmacotherapy as clinically indicated. During a 6‐month run‐in period, both study groups underwent identical AMT algorithms of medication escalations to achieve optimal glycemic control using glucagon‐like peptide‐1 receptor agonists, sodium‐glucose co‐transporter 2 inhibitors, pioglitazone, metformin, and/or insulin [14]. Mean changes in BMI and HbA1c during the 6‐month run‐in period were documented. Following run‐in, a baseline study visit was performed. Post‐run‐in/presurgical demographics, anthropometrics, and centrally measured HbA1c were collected. Subsequently, the VSG group underwent surgery, whereas the AMT group continued to be treated with the AMT medical algorithm. Consistent with perioperative management protocols for participants undergoing VSG, diabetes pharmacotherapy was discontinued on the day of VSG surgery. Freestyle Libre 2 CGMs were placed postoperatively (beginning on days 1–2) in VSG recipients, and at the post‐run‐in baseline study visit following a MMTT (mixed‐meal tolerance test) for AMT participants. Following VSG, participants remained off diabetes medications and advanced from clear liquids on postoperative day‐0 to full liquids by postoperative day‐3, soft solids by week‐3, and finally gradual progression to unrestricted diets. AMT participants remained on their prescribed medications and regular self‐selected diets during the CGM assessment. Both groups were asked to wear CGMs for 14 days. For participants undergoing VSG, inpatient fingerstick and serum glucoses were paired with a time‐matched CGM value within 5 min. Because CGM performance has not been well validated in the immediate postoperative setting following VSG, CGM accuracy was assessed relative to these reference glucose measurements using mean average relative difference (MARD) and Clarke Error Grid [15]. The primary assessment was glycemic normalization post‐VSG. Secondary analyses examined preoperative predictors (HbA1c, race, sex, BMI) of postoperative CGM outcomes. AMT participants served as a comparison cohort of expected variability in medically treated type 2 diabetes in adolescents, recognizing that postoperative participants initially followed a liquid diet, whereas AMT participants consumed unrestricted diets. CGM analyses were performed in R (iglu package) [16, 17]. SAS Studio (SAS Institute, Cary, NC, USA) was used for descriptive statistics, t‐tests, and regression. Descriptive statistics are primarily presented as means ± standard deviations. CGM metrics included glucose management indicator (GMI, a CGM‐based HbA1c predictor), time in range (TIR), coefficient of variability (CV), standard deviation (SD), mean amplitude glycemic excursion (MAGE), percent of glucose values > 140, 180, and 200 mg/dL, percent < 70, 55, and 45 mg/dL, mean 7 a.m. glucose (potential fasting proxy), and overnight (midnight‐6 a.m.) percent < 70, 55, and 45 mg/dL (to assess compression lows). Linear regression tested whether preoperative HbA1c, when adjusted for BMI, predicted postoperative CGM metrics in VSG participants. Further, in separate models we evaluated if the covariates of sex, age, race, ethnicity, and diabetes duration were associated with CGM outcomes. Results Thirty‐three participants underwent VSG and wore CGM (presurgical mean ± SD age 17.6 ± 1.3 years; 67% female, 24% Non‐Hispanic White, 42% Hispanic; HbA1c 7.2% ± 2.1 [55 mmol/mol]; BMI 50.0 ± 9.4 kg/m2; diabetes duration 1.3 ± 0.9 years) (Table 1). Forty participants receiving AMT also wore CGMs (post‐run‐in mean ± SD age 16.9 ± 1.53 years; 53% female; 28% Non‐Hispanic White, 28% Hispanic; HbA1c 7.8% ± 2.4 [62 mmol/mol]; BMI 42.2 ± 7.9 kg/m2; diabetes duration 2.5 ± 1.8 years) (Table 1). VSG participants had higher baseline BMI (p < 0.001) and shorter diabetes duration (p < 0.001) than AMT but otherwise comparable demographics. Medications used at the end of run‐in at the study visit (before VSG) and changes in both BMI and HbA1c at the end of 6‐month run‐in are shown in Table 1 for both groups, with no significant differences in types of medication use or changes in BMI and HbA1c between the groups. TABLE 1Baseline demographics.VSG (n = 33)AMT (n = 40) p Age17.6 (1.3)16.9 (1.5)0.13Sex, n (%)0.22Male11 (33%)19 (48%)Female22 (67%)21 (53%)Race or ethnicity0.47Non‐Hispanic White8 (24%)11 (28%)Non‐Hispanic Black7 (21%)14 (35%)Hispanic14 (42%)11 (28%)Multiple or other4 (12%)4 (10%)HbA1c %, mmol/mol7.2 (2.1), 557.8 (2.4), 620.30 Range 5.2, 33–14.0,130 4.6, 27–13.6, 125 Body mass index, kg/m2 50.0 (9.4)42.2 (7.9)< 0.001* Range 36.3–80.6 32.0–68.3 Diabetes duration in years1.3 (0.9)2.5 (1.8)< 0.001* Range 0.0–4.5 0.7–8.9 Medications, n (%)0.51Metformin monotherapy12 (36%)8 (20%)GLP1‐RA monotherapy3 (9%)3 (8%)Metformin + GLP1‐RA5 (15%)2 (5%)Metformin + SGLT2i3 (9%)3 (8%)Metformin + insulin3 (9%)3 (8%)Other combo of 2 medications3 (9%)4 (10%)Combo of ≥ 3 medications3 (9%)15 (38%)None1 (3%)2 (5%)Changes during 6‐month run‐in periodΔ Body mass index, kg/m2 0.4 (1.6)−0.01 (1.9)0.32Δ HbA1c %−0.02 (1.4)−0.1 (2.1)0.85 Note: Baseline participant demographics for the group undergoing vertical sleeve gastrectomy (VSG) and the advanced medical therapy (AMT) group. Data are listed in mean (standard deviation) unless otherwise specified. Data of both groups compared by t test.*Indicates statistical significance. Baseline demographics. Note: Baseline participant demographics for the group undergoing vertical sleeve gastrectomy (VSG) and the advanced medical therapy (AMT) group. Data are listed in mean (standard deviation) unless otherwise specified. Data of both groups compared by t test. Indicates statistical significance. CGM accuracy was supported by 59 available serum and point‐of‐care paired glucose readings from 12 participants and yielded a MARD of 9.87%. Clarke Error Grid analysis placed 54 values in zone A and 5 in zone B, demonstrating that all CGM values would result in appropriate clinical decision‐making (Figure S1). Mean wear time was similar between groups (VSG 10.5 ± 4.3 days; AMT 10.3 ± 4.1 days) (Table 2). Representative CGM tracings are depicted in Figure 1A,B. Postoperatively, mean glucose and GMI were markedly lower in VSG (83.5 ± 22.9 mg/dL; 5.3 ± 0.6%) versus AMT participants (150.0 ± 79.0 mg/dL; 6.9 ± 1.9%), both p < 0.001). VSG participants had fewer CGM values > 140, 180, and 200 mg/dL (all p < 0.001) but more values < 70, 55, and 45 mg/dL (all p < 0.05). TIR in VSG versus AMT participants was similar (68.0 ± 30.8% vs. 69.8 ± 31.4%, p = 0.812) although more values < 70 mg/dL were seen in VSG participants versus more values > 200 mg/dL in AMT participants. TABLE 2CGM metrics.VSG (n = 33)AMT (n = 40) p Days of wear, mean (SD)10.5 (4.3)10.3 (4.1)0.814 Range 0.3–15.5 1.0–15.1 Active percent56.9 (24.8)69.4 (20.1)0.027* Range 17.9–100 10.2–99.9 Glucose management indicator5.3 (0.6)6.9 (1.9)< 0.001* Range 4.5–7.3 5.1–12.4 Coefficient of variability17.5 (6.6)26.6 (6.6)< 0.001* Range 9.2–36.0 8.1–41.4 Standard deviation15.0 (9.0)39.3 (21.4)< 0.001* Range 7.5–45.8 15.0–99.7 Mean amplitude glycemic excursion26.9 (16.3)81.3 (41.2)< 0.001* Range 8.7–81.1 29.0–185.0 Time in range (70–180 mg/dL)68.0 (30.8)69.8 (31.4)0.812 Range 5.0–100 0–99.4 Mean glucose (mg/dL)83.5 (22.9)150.0 (79.0)< 0.001* Range 48.1–164.8 74.7–377.8 % Above 140 mg/dL4.6 (14.3)37.5 (36.0)< 0.001* Range 0–74.9 0–100 % Above 180 mg/dL1.6 (5.8)24.2 (34.5)< 0.001* Range 0–14.8 0–100 % Above 200 mg/dL0.8 (3.0)20.4 (33.0)< 0.001* Range 0–14.8 0–100 % Below 45 mg/dL4.0 (10.8)0.4 (1.0)0.036* Range 0–46.7 0–4.6 % Below 55 mg/dL8.8 (19.8)1.1 (2.3)0.014* Range 0–81.7 0–10.9 % Below 70 mg/dL30.4 (31.8)6.0 (8.2)< 0.001* Range 0–95.0 0–36.0 Overnight (12 a.m.–6 a.m.) % below 45 mg/dL4.5 (10.7)0.5 (2.1)0.021* Range 0–38.5 0–13.1 Overnight (12 a.m.–6 a.m.) % below 55 mg/dL11.5 (22.8)1.7 (4.2)0.008* Range 0–100 0–23.5 Overnight (12 a.m.–6 a.m.) % below 70 mg/dL37.9 (37.1)8.6 (11.5)< 0.001* Range 0–100 0–49.7 Mean 7 a.m. glucose mg/dL81.8 (22.3)136.8 (73.6)< 0.001* Range 46.3–149.7 67.6–353.6 Note: Participant CGM metrics for the group undergoing vertical sleeve gastrectomy (VSG) and the advanced medical therapy (AMT) group. Data is listed in mean (standard deviation) and range. Data of both groups compared by t test.*Indicates statistical significance. CGM metrics. Note: Participant CGM metrics for the group undergoing vertical sleeve gastrectomy (VSG) and the advanced medical therapy (AMT) group. Data is listed in mean (standard deviation) and range. Data of both groups compared by t test. Indicates statistical significance. (A) VSG post‐operative CGM tracings. (B) AMT CGM Tracings. Representative CGM tracings from adolescents with type 2 diabetes who underwent VSG (A) and those receiving AMT (B). Each tracing displays the corresponding baseline HbA1c and calculated glucose management indicator (GMI). The tracings illustrate marked glycemic improvement following VSG compared with AMT. Mean 7 a.m. glucose (potentially representing fasting) was lower in VSG participants (81.8 ± 22.3 mg/dL) versus AMT participants (136.8 ± 73.6 mg/dL) (p < 0.001). Overnight glucoses (12 a.m.–6 a.m.) were also significantly lower in VSG participants across all values < 70, 55, and 45 mg/dL versus AMT participants (all p < 0.05). Glycemic variability (CV, SD, MAGE) was lower in VSG versus AMT participants. This included lower CV (17.5 ± 6.6 vs. 26.6 ± 6.6), SD (15.0 ± 9.0 vs. 39.3 ± 21.4) and MAGE (26.9 ± 16.3 vs. 81.3 ± 41.2), all p < 0.001. Only one VSG participant had a postoperative GMI in the diabetes‐range (7.3%), corresponding to the individual with the highest preoperative HbA1c (13.4%, 123 mmol/mol) and highest CGM MAGE. Five (15%) additional VSG participants had postoperative GMI in the prediabetes‐range (5.7%–6.4%), all with the next highest preoperative HbA1c values (8.4%–10.9%, 68–96 mmol/mol). In contrast, 15/40 (37.5%) AMT participants had diabetes‐range GMI (6.5%–12.3%) and 17/40 (42.5%) had prediabetes‐range GMI (5.7%–6.3%). Linear regression adjusting for BMI showed preoperative HbA1c significantly predicted postoperative CGM metrics (GMI, CV, SD, MAGE, percent of values > 140, 180, and 200 mg/dL, mean glucose, mean 7 a.m. glucose, and overnight percent < 70 mg/dL) (Table 3). Sex, age, race, ethnicity, and diabetes duration were not associated with CGM outcomes. TABLE 3Preoperative HbA1c as a predictor of post‐VSG CGM metrics, adjusted for BMI.Outcomeß estimateConfidence interval p Glucose management indicator0.2210.150–0.292< 0.001* Coefficient of variability2.0621.024–3.101< 0.001* Standard deviation3.9202.887–4.953< 0.001* Mean amplitude glycemic excursion6.7514.839–8.662< 0.001* Time in range2.833−3.311 to 8.9760.353% Above 140 mg/dL6.2774.690–7.864< 0.001* % Above 180 mg/dL2.3701.625–3.115< 0.001* % Above 200 mg/dL1.2290.830–1.628< 0.001* % Below 70 mg/dL−5.231−11.360 to 0.8980.091% Below 55 mg/dL−0.569−4.413 to 3.2750.764% Below 45 mg/dL−0.161−2.289 to 1.9670.878Mean glucose9.2646.296–12.231< 0.001* Mean 7 a.m. glucose8.7905.880–11.701< 0.001* Overnight % below 70 mg/dL−7.408−14.357 to −0.4590.038* Overnight % below 55 mg/dL−1.458−6.014 to 3.0980.517Overnight % below 45 mg/dL−0.681−2.841 to 1.4800.523 Note: Linear regression adjusting for BMI of preoperative HbA1c as a predictor for post‐VSG metrics.*Indicates statistical significance. Preoperative HbA1c as a predictor of post‐VSG CGM metrics, adjusted for BMI. Note: Linear regression adjusting for BMI of preoperative HbA1c as a predictor for post‐VSG metrics. Indicates statistical significance. Discussion We show in the ST2OMP study that adolescents with type 2 diabetes demonstrated rapid postoperative glycemic normalization immediately following VSG, despite being off of diabetes medications. VSG participants also had significantly more CGM glucose values < 70, 55, and 45 mg/dL. Post‐VSG glucose variability (MAGE, CV, SD), mean glucose, and GMI were also lower versus AMT participants and comparable to published CGM metrics in adolescents without diabetes [18]. We also found preoperative HbA1c strongly predicted postoperative glycemic outcomes in VSG participants, indicating that the ability to obtain better preoperative control predicts rapid normalization without pharmacotherapy postoperatively and correlates with nearly all CGM metrics. While glycemic normalization following Roux‐en‐Y gastric bypass has been described in adults and youth, ST2OMP is the first study to characterize these findings in adolescents with type 2 diabetes following VSG or to have a medically treated control group. AMT participants in ST2OMP provided a comparison to illustrate CGM patterns in adolescents with type 2 diabetes, a population with limited published CGM data. Despite optimized pharmacotherapy with newer diabetes agents, AMT participants still exhibited persistent hyperglycemia and higher glycemic variability across all metrics relative to VSG participants. Although mean TIR was similar between groups, it is important to note that AMT participants had more time above range (24%), while VSG participants had more time below range (30%). Post‐VSG hypoglycemia may be due to alterations in anatomy and in gut hormone responses. However, some low blood glucose levels we detected may represent artificial “compression lows,” where external pressure on the CMG sensor (such as laying on the device during sleep) causes falsely lower readings, particularly overnight. Still, given that the VSG group had significantly more values < 70, 55, and 45 mg/dL than the AMT group, at least a portion of these is likely to be accurate versus sensor artefact. It is important to note that values < 45 mg/dL were rare, and no participants had symptomatic hypoglycemia requiring third‐party assistance. These findings highlight the importance of counselling patients about low blood glucose risk and ensuring access to a glucometer for symptom confirmation. We also evaluated CGM accuracy in adolescents undergoing VSG. Employing MARD and Clarke Error Grid Analysis, CGM demonstrated good clinical accuracy relative to fingerstick and serum glucose measurements, supporting appropriate clinical decision‐making [15]. Our MARD was comparable to current FDA‐approved CGM reports [19], supporting CGM as a reliable clinical tool in adolescents with severe obesity undergoing MBS. Our study has multiple strengths. One is the important new data supporting VSG in a high‐risk population, and insights into early changes independent of weight loss. Another is the inclusion of a run‐in period where both study groups were treated with the same medication algorithm to allow the closest comparison group with comparable glycemia, and the ability to compare VSG to a contemporary control group treated with more effective medications than studied in the past. In addition, we assessed glycemia with parallel methods, allowing CGM validation in this population. The 2‐site design allowed for enhanced racial/ethnic diversity, yet HbA1c was measured at a central laboratory, and we employed standardized medication algorithms, medication withdrawal for study visits and post‐operative medication cessation and feeding regimen, allowing harmonized procedures across sites. This study also has several limitations. First, the AMT group had longer diabetes duration and lower BMI, limiting direct CGM comparisons between VSG and AMT groups. Second, low CGM glucose values were not confirmed by serum or point‐of‐care glucoses, making it difficult to distinguish true hypoglycemia from possible overnight compression lows or sensor inaccuracy. Additionally, CGM glucose values represent estimated glucose concentrations derived from interstitial fluid using proprietary algorithms, which may not be specifically validated in the post‐bariatric surgery population. Third, in discussing reliability of CGM for glycemic accuracy, although we report a clinically acceptable MARD, paired glucose values were not available for all participants undergoing VSG, limiting the generalizability. A further consideration is the difference in dietary intake between groups: participants undergoing VSG were tolerating a postoperative liquid diet during CGM wear, whereas AMT participants self‐selected their diet after standard nutrition counselling, and detailed intake data were not collected. The reduced caloric intake in the early postoperative period is best understood not as an alternative explanation to surgery but as one of the proximate mechanisms through which bariatric surgery improves glycemia in the immediate postoperative window, alongside altered enteroendocrine signalling; very‐low‐calorie dietary restriction has been shown to reproduce the early metabolic effect of bariatric surgery, indicating convergence on a shared physiology rather than two competing explanations [20]. Several observations argue that the post‐surgical hypocaloric state alone does not account for our findings. First, non‐bariatric major abdominal surgery under general anaesthesia produces a well‐characterized, predictable counterregulatory stress response that raises glucose, with the effect most pronounced in the first 24–48 postoperative hours—precisely the interval captured by CGM in this study [21, 22]. Bariatric surgery is a documented exception to this pattern: in adults, glucose and insulin requirements fall markedly within the same early postoperative window, before meaningful weight loss, through weight‐independent enteroendocrine and hepatic mechanisms [23]. Glycemic normalization off all diabetes pharmacotherapy in our adolescent cohort, therefore, occurred against the higher post‐surgical glucose excursions that would be expected of major abdominal surgery and recapitulated the established procedure‐specific adult bariatric response. Second, had a shared postoperative diet been the principal driver, postoperative glycemic metrics would be expected to converge irrespective of preoperative status; instead, preoperative HbA1c independently and dose‐dependently predicted postoperative CGM metrics (Table 3), indicating that outcomes tracked individual residual β‐cell reserve rather than the common dietary exposure. Third, AMT participants, who completed the identical 6‐month medical optimization algorithm, did not achieve comparable glycemic profiles. The comparison the study supports is thus VSG versus optimized contemporary medical therapy in clinically similar adolescents. These considerations notwithstanding, the relative contributions of surgery, enteroendocrine adaptation, and reduced caloric intake cannot be fully partitioned in this design, and CGM findings during the immediate postoperative period may differ once the diet is liberalized—underscoring the need for longitudinal follow‐up to assess durability of glycemic improvement and resolution of diabetes, which we are performing via repeated HbA1c and MMTT over 2 years of longitudinal follow‐up in ST2OMP. Finally, a limitation of this study was variability in CGM active time, including some participants with lower sensor capture, which may reduce the precision of CGM‐derived metrics and should be considered when interpreting glycemic outcomes. Conclusions Most adolescents with type 2 diabetes achieved early postoperative glycemic normalization post‐VSG, with lower preoperative HbA1c predicting better control postoperatively. VSG correlated with more CGM values < 70, 55, and 45 mg/dL. Additional work is needed to understand the durability of glycemic patterns and whether low CGM readings reflect clinically relevant hypoglycemia. Author Contributions N.S. completed CGM data analysis, performed statistical tests and interpretation and wrote the first draft of and edited the manuscript. A.S.S., K.N., M.K., L.S., S.A.X., M.H., T.H.I., and T.M.J. designed the original study, wrote the study protocol, and edited and reviewed the manuscript. A.B., A.R., and K.W. contributed to study data organization and reviewed the manuscript. All authors approved the final version of the manuscript. Funding This study was supported by a grant from the National Institutes of Health (R01DK119450) and CGM product support from Abbott. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Clarke Error Grid: Time‐matched CGM to serum or point‐of‐care glucose values. Clarke Error Grid analysis comparing CGM glucose values with simultaneous reference blood glucose measurements in those undergoing VSG. Zones A and B represent values leading to clinically accurate or benign treatment decisions, while zones C–E represent increasingly significant clinical risk. All points fall within zones A and B, indicating clinically acceptable accuracy.